Anne-Lise B√∏rresen-Dale

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Magali Olivier, Anita Langer√∏d, Patrizia Carrieri et al. · Clinical Cancer Research · 2006 · 600 citations

Medicine, Molecular Medicine, Oncology +14

Re-expression of E-cadherin, ?-catenin and ?-catenin, but not of ?-catenin, in metastatic tissue from breast cancer patients

I. K. Bukholm, Jahn M. Nesland, Anne-Lise B√∏rresen-Dale · The Journal of Pathology · 2000 · 207 citations

Medicine, Cancer Biology, Oncology +17

Microarrays in primary breast cancer--lessons from chemotherapy studies.

PerEystein L�nning, Therese S�rlie, Charles M. Perou et al. · Endocrine Related Cancer · 2001 · 39 citations · Full text

Medicine, Molecular Biology, Oncology +14

Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study

Kirsten Laake, Virpi Launonen, Dieter Niederacher et al. · Genes Chromosomes and Cancer · 1999 · 38 citations

Life Sciences, Genetics, Molecular Genetics +17

TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus

Hanne Skomedal, Gunnar B. Kristensen, Jahn M. Nesland et al. · The Journal of Pathology · 1999 · 35 citations

Medicine, Molecular Biology, Oncology +17